Health Care & Life Sciences » Pharmaceuticals | Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
Depreciation, Depletion & Amortization
129.00
124.00
193.00
282.00
431.00
576
Other Funds
1,516.00
5,573.00
11,757.00
13,145.00
11,963.00
13,274
Funds from Operations
27,991.00
61,045.00
71,239.00
64,053.00
102,358.00
58,308
Changes in Working Capital
3,485.00
3,422.00
5,468.00
287.00
4,308.00
1,320
Net Operating Cash Flow
24,506.00
57,623.00
76,707.00
63,766.00
98,050.00
59,628
Capital Expenditures
129.00
191.00
838.00
393.00
771.00
Net Investing Cash Flow
129.00
191.00
838.00
393.00
771.00
Issuance/Reduction of Debt, Net
1,232.00
6,126.00
4,646.00
-
-
Net Financing Cash Flow
118,268.00
76,144.00
162,415.00
333.00
93,146.00
Net Change in Cash
93,633.00
18,330.00
84,870.00
63,826.00
5,675.00
Free Cash Flow
24,635.00
57,814.00
77,545.00
64,159.00
98,821.00
Change in Capital Stock
119,500.00
82,270.00
167,061.00
333.00
93,146.00

About Tetraphase Pharmaceuticals

View Profile
Address
480 Arsenal Street
Watertown Massachusetts 02472
United States
Employees -
Website http://www.tphase.com
Updated 07/08/2019
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.